Patents For AIDS Drugs Would Hike Prices Without India Safeguards
This article was originally published in PharmAsia News
If patents are granted in India for AIDS drugs, their cost could increase so much HIV patients in the country could have problems getting them, the government said. But the Union Minister of State for Chemicals and Fertilisers also said India's Patent Act contains safeguards against that event. The country also has access to anti-retrovirals in bulk from international companies bidding to supply the drugs, the minister said. India also has an agreement with an international agency to supply free AVR drugs for children and other second-line ARV drugs that would be administered for free. (Click here for more
You may also be interested in...
The company has no development programs left in its R&D pipeline and will focus entirely on the commercialization of IBS drug Linzess while seeking late-stage assets from external sources.
The documents issued by the US agency on 29 September set slightly different accuracy standards, reflecting the increased fragility of hospital patients.
The US FDA commissioner published a blog post commending and highlighting the work device center staff have done during the pandemic to speed tests and devices to market to save lives.